Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OPDC researchers have developed a new genetic mouse model of Parkinson's to track the earliest changes that take place in the brain.

The knowledge gained from their groundbreaking study, published in the leading scientific journal PNAS, could pave the way for new treatments that can slow or stop Parkinson's in its tracks. This study is the first to show that the way the chemical messenger dopamine is stored and released is affected at the very start of the process – before Lewy bodies appear.

Read the press release: http://www.parkinsons.org.uk/news/3-october-2013/clues-about-early-stages-parkinsons-new-mouse-model

Similar stories

Researchers characterise the landscape of somatic mutations among acid-base transporters in human cancers

A new paper lead by DPhil student Bobby White and Professor Pawel Swietach from DPAG’s Swietach Group explores the role that somatic mutations affecting plasma membrane acid-base transporters play in human cancer evolution. The team identify acid-base transporters that are essential to cancer cell survival, and those where somatic mutations are likely to play a driving role in certain cancer types.